focus -WSS

focus

author：comprehensive 2025-09-29 21:26:05 - browse：56971

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： How dance can help health care workers heal from trauma

explore

knowledge

WSS

TikTok cracks down on users posting about weight loss drugs

Celebrate National Dole Whip Day for 3 days this week at Disney

Kaiser's Risant Health gobbled up Geisinger. Who is next?

'Reaching a detente': STAT's Helen Branswell on covering Covid

Ultragenyx gene therapy for rare liver ailment succeeds in late

Why the Crimean Bridge is key to Russia's war in Ukraine

explore

focus

leisure time

Medicare details structure of new drug price negotiation program

BMI, flaws aside, is found to be useful estimate of body fat in youth

Jerome Adams on the need for new antivirals for Covid

'Reaching a detente': STAT's Helen Branswell on covering Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

'Reaching a detente': STAT's Helen Branswell on covering Covid

Hepatitis C has a cure — but many Americans still lack access to it

DOJ, FTC to increase scrutiny of all types of health care mergers

Drug repurposing or repositioning? The language matters

Trump got a 'target letter.' What is one and what does it mean?

focus

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Celebrate National Dole Whip Day for 3 days this week at Disney

Cord blood banking comes at a high cost to babies

Cord blood banking comes at a high cost to babies

Stanford updates investigation of president’s past research

Wikipedia

explore

knowledge

focus